PriceTargets.com logo

Synaptogenix - SNPX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 372.97%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.96 As of 10/11/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SNPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synaptogenix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNPX

Analyst Price Target is $14.00
▲ +372.97% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Synaptogenix in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 372.97% upside from the last price of $2.96.

This chart shows the closing price for SNPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Synaptogenix. This rating has held steady since December 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/11/2024Maxim GroupUpgradeHold ➝ Buy$14.00
12/19/2022Maxim GroupDowngradeBuy ➝ Hold
4/12/2022Maxim GroupInitiated CoverageBuy$350.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/13/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/12/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/12/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Synaptogenix logo
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.96
Low: $2.87
High: $2.96

50 Day Range

MA: $3.37
Low: $2.85
High: $3.96

52 Week Range

Now: $2.96
Low: $2.72
High: $10.25

Volume

1,486 shs

Average Volume

38,693 shs

Market Capitalization

$3.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Synaptogenix?

The following Wall Street sell-side analysts have issued research reports on Synaptogenix in the last year: Maxim Group.
View the latest analyst ratings for SNPX.

What is the current price target for Synaptogenix?

1 Wall Street analysts have set twelve-month price targets for Synaptogenix in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 373.0%. Maxim Group has the highest price target set, predicting SNPX will reach $14.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $14.00 for Synaptogenix in the next year.
View the latest price targets for SNPX.

What is the current consensus analyst rating for Synaptogenix?

Synaptogenix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNPX will outperform the market and that investors should add to their positions of Synaptogenix.
View the latest ratings for SNPX.

What other companies compete with Synaptogenix?

Other companies that are similar to Synaptogenix include Aprea Therapeutics, Mannatech, Cara Therapeutics, Aytu BioPharma and Edesa Biotech. Learn More about companies similar to Synaptogenix.

How do I contact Synaptogenix's investor relations team?

Synaptogenix's physical mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company's listed phone number is 973-242-0005 and its investor relations email address is [email protected]. The official website for Synaptogenix is www.synaptogen.com. Learn More about contacing Synaptogenix investor relations.